Medical Cannabis News

Synonyms: 
mmj
Fri
18
May

CEO of Canopy Growth says cannabis legalization will result in fewer opioid prescriptions

Bruce Linton, founder and CEO of Canada’s largest marijuana company, Canopy Growth Corporation, said that legalizing cannabis at the federal level in the US could result in fewer opioid and other addictive prescriptions.

The interview with CNBC’s Mad Money host, Jim Cramer, took place Thursday following Canopy Growth recently applying to become the first cannabis producer to be listed on the New York Stock Exchange.

Linton explained that Canopy Growth has both a medical and recreational division and that on the recreational side; he expects that the company’s partnership with Constellation Brands will result in a new class of low-calorie beverages. He said that the possibilities within the medical division are still emerging.

Fri
18
May

Cannvas to sponsor medical cannabis week

Cannvas MedTech Inc. ("Cannvas MedTech" or the "Company"), a leading business technology company within the cannabis space, is pleased to announce its lead sponsorship role at the upcoming Medical Cannabis Week in Toronto. This inaugural event brings together the thought leaders in the Canadian medical cannabis sector and is presented by Business of Cannabis in partnership with Cannvas MedTech, WeedMD, Ample Organics, TechTO, HealthTO, SheCann, Blakes, Cassels & Graydon LLP, RNMKR PR, Salesforce, Emblem and other leading industry partners.

Thu
17
May

Reformulary Group to develop cannabis formulary

The Reformulary Group Inc. has formed a cannabis formulary committee that will review evidence for medical marijuana and provide expert opinions and criteria for its use, including lines of therapy, specific strains, grams per indication, mode of consumption and quantity limits.

The committee is also aiming to create a registry to capture patient-reported data, which will then help to build a cannabis formulary.  

“For Canadian employers that choose to cover medical cannabis, our cannabis formulary — called Cannabis Standard — will be an essential product to access the best available evidence and expert advice,” said Helen Stevenson, founder and chief executive officer of the Reformulary Group, in a press release.

Wed
16
May

How using a cannabis-related product can aid in recovery

CBD oil doesn't produce a high but is suggested to aid in runner's recovery.

Cannabis and cannabis-related products are becoming much more prevalent and accepted in Canada. This acceptance has lead to a deeper exploration of cannabis, and what the drug can do to help athletes. While cannabis in its psychoactive form remains illegal both in and out of competition, there is an emerging cannabis-related product called cannabidiol that is showing benefits for runners. It is suggested that cannabidiol can lessen inflammation and improve recovery time.

Tue
15
May

Telemedicine revolutionizing the medical cannabis industry

Telemedicine is revolutionizing the cannabis industry and as a result, companies like NamasteMD can provide patients more accessibility to medical cannabis than ever before. (123rf)

Mon
14
May

Emblem (TSXV: $EMC.V) and Canntab Therapeutics announce Health Canada approval for R&D of #cannabinoid-based oral sustained release formulation

Emblem Corp. (TSXV: EMC) (TSXV: EMC.WT) ("Emblem" or the "Company") and Canntab Therapeutics Limited (CSE: PILL) ("Canntab") are pleased announce to receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the "Sustained Release Product" or the "Product"), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab's partnership to develop long-acting cannabis formulations.

Fri
11
May

Cannabidiol oil won't get you buzzed but it could get you busted

CBD oil is a controlled substance — and the 'jury is still out' on its health benefits.

Cannabidiol oil, or CBD, is generating a lot of buzz in the world of alternative medicine and many Canadians are buying in.

The oil, which is extracted from marijuana plants, doesn't have the same mind-altering effects as smoking pot. People rub it on their achy joints or put it under their tongue to help them sleep. Some purveyors say it's completely legal in Canada and can be used for a long list of ailments, including epilepsy and multiple sclerosis.

But federal authorities say CBD oil, which is widely available at head shops and online, is indeed illegal without a medical marijuana prescription. And its purported health benefits are also still in question.

Fri
11
May

Medical cannabis clinic focuses on education

A local clinic is embracing a more personal, science-based approach when it comes to prescribing medical cannabis for qualified patients.

After its initial launch in January, the Clinic Network of Canada (CNC) hosted the official grand opening of a new medical cannabis resource centre and pain management clinic at Pure Clinics in Sherwood Park on April 12.

Mike Lukacs, a cannabis educator and client services representative with CNC, said the clinic’s approach represents a necessary shift from traditional models in existence today.

“If people look at cannabis from a medical standpoint, and they have a treatable condition, they don’t just want a prescription and then to be left to figure it out themselves,” he noted.

Fri
11
May

Cannabis-sector CEOs expect Canadian sales post-legalization will outpace expectations

Baby boomers expected to drive sales as they switch to cannabis from other medications.

Cannabis-sector CEOs are bullish about the prospect for sales once Canada legalizes marijuana and say that the market will soar far above many estimates.

At the Arcview Group’s cannabis investment conference on May 2, the CEOs of three Canadian cannabis companies were united in predicting the legal cannabis market in Canada will fast outpace expectations.

A recent New Frontier Data report pinned the domestic cannabis market in Canada at $9.2 billion by 2025, sustained by higher average medical consumption. More conservative estimates pin federal sales at $4.5 billion by 2027.

Fri
11
May

Aurora Cannabis should soon pass Canopy Growth Corp. in medical pot sales, PI says

Following the company’s third quarter results, PI Financial analyst Jason Zandberg is feeling bullish about Aurora Cannabis (TSX:ACB).

On May 8, ACB posted its Q3, 2018 results. The company lost $20.79-million on revenue of $16.1-million, a topline that was up 211 per cent over last year’s third quarter.

Pages

Subscribe to RSS - Medical Cannabis News